Clinical Trials Browser

Phase 1/2 × tisotumab vedotin × 90 days × Clear all

NCT03786081 2026-03-13

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms